PT-141 10mg – Bremelanotide CNS Research Peptide | Tides Lab

PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist derived from Melanotan 2, studied in laboratory research investigating central melanocortin signalling pathways. Unlike peripherally acting compounds, PT-141 is of particular interest in research examining CNS-mediated receptor activity due to its ability to cross the blood-brain barrier in experimental models.

This 10mg lyophilised formulation is supplied at ≥99% purity and intended strictly for laboratory research purposes.

Key Features

• 10mg lyophilised PT-141 (Bremelanotide)
• Melanocortin receptor agonist with CNS activity in research models
• Derived from Melanotan 2; studied for central signalling mechanisms
• ≥99% purity
• Research use only
• Fast Australian shipping

Mechanism Overview

PT-141 is a cyclic heptapeptide analogue of Melanotan 2, sharing its core melanocortin receptor binding profile but with a distinct research focus on centrally mediated signalling. It acts as an agonist at MC3R and MC4R subtypes, both of which are expressed in hypothalamic nuclei involved in neuroendocrine and autonomic regulation.

MC4R in particular has been extensively studied in the context of hypothalamic circuitry governing physiological arousal responses. In preclinical models, PT-141's agonism at hypothalamic MC4R has been associated with downstream activation of dopaminergic pathways — specifically within the mesolimbic system — which has positioned it as a key reference compound in research examining centrally mediated sexual arousal signalling and reward pathway modulation.

Unlike PDE5 inhibitors and other compounds that act peripherally through vascular mechanisms, PT-141's studied activity originates at the level of the CNS. This mechanistic distinction has made it a valuable tool compound in neuropharmacological research seeking to isolate central versus peripheral contributions to arousal-related physiological responses.

MC3R activity has been investigated separately in models relating to energy homeostasis and anti-inflammatory signalling, adding a secondary dimension to PT-141's research profile beyond its primary CNS applications.

Its cyclic structure contributes to proteolytic resistance compared to linear melanocortin peptides, supporting its use in longer-duration in vitro and in vivo experimental models.

Stability and Handling

PT-141 is supplied in lyophilised (freeze-dried) form to preserve peptide stability during storage and transport.

Standard laboratory handling considerations include:

• Refrigerated storage following reconstitution
• Protection from direct light exposure
• Avoiding repeated temperature fluctuations

Research Use Only

PT-141 is supplied strictly for laboratory research and educational purposes. It is not approved for therapeutic use and is not intended for human consumption.